A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas.

ABSTRACT:

SUBMITTER: Rindone G 

PROVIDER: S-EPMC9898594 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature